From the Guidelines
IDDM2 is not directly related to type 2 diabetes, but rather is a genetic susceptibility locus for type 1 diabetes mellitus located on chromosome 11p15.5, as described in the context of genetic factors influencing diabetes development 1.
Key Points
- IDDM2 involves a variable number of tandem repeats (VNTR) in the promoter region of the insulin gene, affecting insulin expression in the thymus and contributing to autoimmune destruction of pancreatic beta cells in type 1 diabetes.
- The provided evidence primarily discusses type 2 diabetes, its diagnosis, and management, without directly addressing IDDM2 or its implications for type 1 diabetes.
- Type 2 diabetes is characterized by relative insulin deficiency and peripheral insulin resistance, with various causes and risk factors, including age, obesity, and lack of physical activity 2, 3.
Diagnosis and Management
- The diagnosis of type 2 diabetes is based on criteria such as fasting plasma glucose, 2-hour plasma glucose during an oral glucose tolerance test, and A1C levels, as outlined in the standards of medical care in diabetes 1.
- Management of type 2 diabetes focuses on lifestyle modifications, such as diet and exercise, and pharmacologic treatment of hyperglycemia to improve insulin resistance and reduce the risk of complications.
Importance of Accurate Diagnosis
- Accurate diagnosis and distinction between type 1 and type 2 diabetes are crucial for appropriate management and treatment, as the two forms of diabetes have different underlying pathophysiologies and require different therapeutic approaches.
- The most recent and highest quality study 3 emphasizes the importance of understanding the classification and diagnosis of diabetes to provide optimal care for patients with type 2 diabetes.
From the Research
Iddm2 Overview
- Iddm2, also known as type 1 diabetes mellitus (T1DM), is a chronic condition characterized by a complete deficiency in insulin production 4.
- The management of T1DM in adults involves a combination of insulin therapy, glucose monitoring, and lifestyle modifications 5, 6.
Insulin Therapy
- Most patients with T1DM should follow a regimen of multiple daily injections of basal/bolus insulin, but those not meeting individual glycemic targets or those with frequent or severe hypoglycemia or pronounced dawn phenomenon should consider continuous subcutaneous insulin infusion 5.
- Basal insulin analogues with a reduced peak profile and an extended duration of action with lower intraindividual variability relative to neutral protamine Hagedorn insulin are preferred 5.
- Rapid-acting prandial analogues (aspart, glulisine, lispro) are preferred over regular human insulin for prandial glycemic control 5.
Glucose Monitoring
- Continuous glucose monitoring (CGM) technology addresses many of the gaps in self-monitoring of blood glucose (SMBG) and provides more detailed information to guide management 4, 7.
- CGM has been shown to improve glycemic control and reduce the risk of hypoglycemia and hyperglycemia 4, 7.
Future Directions
- The development of insulin titration guidelines is necessary to improve glucose control metrics and enable patients with T1DM to achieve recommended glycemic goals 8.
- The use of large device databases and optimized total daily doses of insulin can provide clear insulin titration guidelines and improve the management of T1DM 8.